FDA) delayed approval due to concerns regarding potential hypersensitivity reactions and effects on coagulation tests, 7 which were ultimately satisfied. [8] [9] [10] We are interested in better understanding global experience with sugammadex and the impact, if any, of pharmacoeconomics on post-marketing policies. The present data were analysed from an ongoing, Institutional Review Board (IRB)-approved (Emory University, Atlanta, GA, USA, IRB# 00082571) study of a globally utilized anaesthesia calculator app for the Android platform ('Anesthesiologist') 11 12 fitted with a module capable of collecting survey data and app analytics. 13 We used this tool to deploy a survey assessing global patterns of clinical practice and experience with sugammadex. Of 11 863 anaesthesia provider respondents in 183 countries, 5510 (46%) reported sugammadex was available and relevant to their practice and were thus asked additional questions. Due to respondent fatigue, 14 15 not all questions were completed by all respondents. A majority of these providers (72%, Fewer self-limited due to limited drug supply (24%), and very few were concerned about adverse events (7.8%). These trends held true among respondents reporting free, unrestricted access to sugammadex (Table 1 , Q4, subset). Given the advantages of sugammadex over traditional reversal agents and tolerability in a wide range of disease states, 6 we expected stronger adoption of sugammadex. Our findings suggest that cost concerns are the primary driver of limitations in use. It was surprising that institutional policies restricting sugammadex were not common. Even in the relative absence of policies restricting sugammadex use, about two-thirds of anaesthesia providers reported self-imposed limitations on sugammadex administration (66.5%, Table 1, Q4) . This is likewise unexpected as physician knowledge and awareness of medication costs are generally poor, 16 17 and drug costs generally do not impact individual anaesthesia providers directly. Anaesthesia providers appear to be making care decisions with economic concerns of their hospitals and patients in mind. However, the pharmacoeconomics of sugammadex are likely complex as higher drug costs may be offset by decreased operating room recovery times, faster discharge to the ward and fewer complications related to residual neuromuscular block. may not be fully considering these and other means of indirect cost savings. Budgetary silos typically constrain the way in which hospital pharmacy and therapeutics committees conceptualize cost and cost savings as they often emphasize acquisition costs with little regard for potential indirect savings. Such an approach is ill advised as these direct cost considerations must be balanced against possible advantages from a quality and value perspective that are afforded by the use of sugammadex. Further assessment of global and regional variability in the impact of pharmacoeconomics on sugammadex practice patterns may yield further insight into the relatively low prevalence of reported institutional policies. Variations in national or regional healthcare delivery systems and administration may influence the way in which costs are conceptualized, thus influencing clinical approaches to reversal of neuromuscular block and the utilization of sugammadex.
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